The introduction of new techniques into the existing fragment-based drug discovery practices have created significant reductions in time and cost, driving the demand for such practices.
Highlights
The global Fragment-based Drug Discovery market was valued at US$ 365.8 million in 2022 and is anticipated to reach US$ 533.8 million by 2029, witnessing a CAGR of 6.5% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Fragment-based Drug Discovery is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Fragment-based Drug Discovery is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Fragment-based Drug Discovery in Academic and Research Institutions is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Fragment-based Drug Discovery include Astex Pharmaceuticals, Alveus Pharmaceuticals, Beactica, Charles River Laboratories, Crown Bioscience, Emerald BioStructures, Evotec, Kinetic Discovery and Proteros Fragments, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Fragment-based Drug Discovery, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fragment-based Drug Discovery.
The Fragment-based Drug Discovery market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Fragment-based Drug Discovery market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Fragment-based Drug Discovery companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Astex Pharmaceuticals
Alveus Pharmaceuticals
Beactica
Charles River Laboratories
Crown Bioscience
Emerald BioStructures
Evotec
Kinetic Discovery
Proteros Fragments
Sprint Bioscience
Structure Based Design
Sygnature Discovery
Segment by Type
Fragment Screening
Fragment Optimization
Segment by Application
Academic and Research Institutions
Biopharmaceutical Companies
Contract Research Organizations (CROs)
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Fragment-based Drug Discovery companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Fragment-based Drug Discovery 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Fragment Screening
1.2.3 Fragment Optimization
1.3 麻豆原创 by Application
1.3.1 Global Fragment-based Drug Discovery 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Academic and Research Institutions
1.3.3 Biopharmaceutical Companies
1.3.4 Contract Research Organizations (CROs)
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Fragment-based Drug Discovery 麻豆原创 Perspective (2018-2029)
2.2 Fragment-based Drug Discovery Growth Trends by Region
2.2.1 Global Fragment-based Drug Discovery 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Fragment-based Drug Discovery Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Fragment-based Drug Discovery Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Fragment-based Drug Discovery 麻豆原创 Dynamics
2.3.1 Fragment-based Drug Discovery Industry Trends
2.3.2 Fragment-based Drug Discovery 麻豆原创 Drivers
2.3.3 Fragment-based Drug Discovery 麻豆原创 Challenges
2.3.4 Fragment-based Drug Discovery 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Fragment-based Drug Discovery Players by Revenue
3.1.1 Global Top Fragment-based Drug Discovery Players by Revenue (2018-2023)
3.1.2 Global Fragment-based Drug Discovery Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Fragment-based Drug Discovery 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Fragment-based Drug Discovery Revenue
3.4 Global Fragment-based Drug Discovery 麻豆原创 Concentration Ratio
3.4.1 Global Fragment-based Drug Discovery 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Fragment-based Drug Discovery Revenue in 2022
3.5 Fragment-based Drug Discovery Key Players Head office and Area Served
3.6 Key Players Fragment-based Drug Discovery Product Solution and Service
3.7 Date of Enter into Fragment-based Drug Discovery 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Fragment-based Drug Discovery Breakdown Data by Type
4.1 Global Fragment-based Drug Discovery Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Fragment-based Drug Discovery Forecasted 麻豆原创 Size by Type (2024-2029)
5 Fragment-based Drug Discovery Breakdown Data by Application
5.1 Global Fragment-based Drug Discovery Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Fragment-based Drug Discovery Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Fragment-based Drug Discovery 麻豆原创 Size (2018-2029)
6.2 North America Fragment-based Drug Discovery 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Fragment-based Drug Discovery 麻豆原创 Size by Country (2018-2023)
6.4 North America Fragment-based Drug Discovery 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Fragment-based Drug Discovery 麻豆原创 Size (2018-2029)
7.2 Europe Fragment-based Drug Discovery 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Fragment-based Drug Discovery 麻豆原创 Size by Country (2018-2023)
7.4 Europe Fragment-based Drug Discovery 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Fragment-based Drug Discovery 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Fragment-based Drug Discovery 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Fragment-based Drug Discovery 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Fragment-based Drug Discovery 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Fragment-based Drug Discovery 麻豆原创 Size (2018-2029)
9.2 Latin America Fragment-based Drug Discovery 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Fragment-based Drug Discovery 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Fragment-based Drug Discovery 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Fragment-based Drug Discovery 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Fragment-based Drug Discovery 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Fragment-based Drug Discovery 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Fragment-based Drug Discovery 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Astex Pharmaceuticals
11.1.1 Astex Pharmaceuticals Company Detail
11.1.2 Astex Pharmaceuticals Business Overview
11.1.3 Astex Pharmaceuticals Fragment-based Drug Discovery Introduction
11.1.4 Astex Pharmaceuticals Revenue in Fragment-based Drug Discovery Business (2018-2023)
11.1.5 Astex Pharmaceuticals Recent Development
11.2 Alveus Pharmaceuticals
11.2.1 Alveus Pharmaceuticals Company Detail
11.2.2 Alveus Pharmaceuticals Business Overview
11.2.3 Alveus Pharmaceuticals Fragment-based Drug Discovery Introduction
11.2.4 Alveus Pharmaceuticals Revenue in Fragment-based Drug Discovery Business (2018-2023)
11.2.5 Alveus Pharmaceuticals Recent Development
11.3 Beactica
11.3.1 Beactica Company Detail
11.3.2 Beactica Business Overview
11.3.3 Beactica Fragment-based Drug Discovery Introduction
11.3.4 Beactica Revenue in Fragment-based Drug Discovery Business (2018-2023)
11.3.5 Beactica Recent Development
11.4 Charles River Laboratories
11.4.1 Charles River Laboratories Company Detail
11.4.2 Charles River Laboratories Business Overview
11.4.3 Charles River Laboratories Fragment-based Drug Discovery Introduction
11.4.4 Charles River Laboratories Revenue in Fragment-based Drug Discovery Business (2018-2023)
11.4.5 Charles River Laboratories Recent Development
11.5 Crown Bioscience
11.5.1 Crown Bioscience Company Detail
11.5.2 Crown Bioscience Business Overview
11.5.3 Crown Bioscience Fragment-based Drug Discovery Introduction
11.5.4 Crown Bioscience Revenue in Fragment-based Drug Discovery Business (2018-2023)
11.5.5 Crown Bioscience Recent Development
11.6 Emerald BioStructures
11.6.1 Emerald BioStructures Company Detail
11.6.2 Emerald BioStructures Business Overview
11.6.3 Emerald BioStructures Fragment-based Drug Discovery Introduction
11.6.4 Emerald BioStructures Revenue in Fragment-based Drug Discovery Business (2018-2023)
11.6.5 Emerald BioStructures Recent Development
11.7 Evotec
11.7.1 Evotec Company Detail
11.7.2 Evotec Business Overview
11.7.3 Evotec Fragment-based Drug Discovery Introduction
11.7.4 Evotec Revenue in Fragment-based Drug Discovery Business (2018-2023)
11.7.5 Evotec Recent Development
11.8 Kinetic Discovery
11.8.1 Kinetic Discovery Company Detail
11.8.2 Kinetic Discovery Business Overview
11.8.3 Kinetic Discovery Fragment-based Drug Discovery Introduction
11.8.4 Kinetic Discovery Revenue in Fragment-based Drug Discovery Business (2018-2023)
11.8.5 Kinetic Discovery Recent Development
11.9 Proteros Fragments
11.9.1 Proteros Fragments Company Detail
11.9.2 Proteros Fragments Business Overview
11.9.3 Proteros Fragments Fragment-based Drug Discovery Introduction
11.9.4 Proteros Fragments Revenue in Fragment-based Drug Discovery Business (2018-2023)
11.9.5 Proteros Fragments Recent Development
11.10 Sprint Bioscience
11.10.1 Sprint Bioscience Company Detail
11.10.2 Sprint Bioscience Business Overview
11.10.3 Sprint Bioscience Fragment-based Drug Discovery Introduction
11.10.4 Sprint Bioscience Revenue in Fragment-based Drug Discovery Business (2018-2023)
11.10.5 Sprint Bioscience Recent Development
11.11 Structure Based Design
11.11.1 Structure Based Design Company Detail
11.11.2 Structure Based Design Business Overview
11.11.3 Structure Based Design Fragment-based Drug Discovery Introduction
11.11.4 Structure Based Design Revenue in Fragment-based Drug Discovery Business (2018-2023)
11.11.5 Structure Based Design Recent Development
11.12 Sygnature Discovery
11.12.1 Sygnature Discovery Company Detail
11.12.2 Sygnature Discovery Business Overview
11.12.3 Sygnature Discovery Fragment-based Drug Discovery Introduction
11.12.4 Sygnature Discovery Revenue in Fragment-based Drug Discovery Business (2018-2023)
11.12.5 Sygnature Discovery Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Astex Pharmaceuticals
Alveus Pharmaceuticals
Beactica
Charles River Laboratories
Crown Bioscience
Emerald BioStructures
Evotec
Kinetic Discovery
Proteros Fragments
Sprint Bioscience
Structure Based Design
Sygnature Discovery
听
听
*If Applicable.
